We can leverage many of our proprietary patient-derived xenograft (PDX) models and cell lines to perform integrated preclinical profiling of anticancer agents. Many of the models in our library correspond to established cell lines that have been derived from the xenograft model. Currently, we have more than 60 of these cell lines, which have been established with high conservation respective to their parent cell lines.
This unique capability enables you to use the same tumor entity throughout your 2D, 3D and in vivo assays. This approach to your program keeps efficiency and cost in mind, while letting you quickly collect the best study data. By using the same tumor model in your assays, we can leverage our extensive biomarker database, and offer insight and clinically relevant information throughout the life of your study.